StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a report published on Saturday morning. The firm issued a sell rating on the medical research company’s stock.
OpGen Trading Down 5.9 %
NASDAQ:OPGN opened at $1.60 on Friday. The company’s 50-day moving average is $1.86 and its two-hundred day moving average is $2.61. OpGen has a 1-year low of $1.46 and a 1-year high of $9.90.
OpGen (NASDAQ:OPGN – Get Free Report) last issued its quarterly earnings data on Monday, August 19th. The medical research company reported ($1.18) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter.
About OpGen
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Featured Articles
- Five stocks we like better than OpGen
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- There Are Different Types of Stock To Invest In
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Investing In Automotive Stocks
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.
